SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
Sponsor: Stemline Therapeutics, Inc.
This PHASE1/PHASE2 trial investigates Acute Myeloid Leukemia and is currently terminated or withdrawn. Stemline Therapeutics, Inc. leads this study, which shows 13 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Nov 2024 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2022 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Completed → Terminated
▶ Show 8 earlier versions
-
Jan 2021 — Feb 2022 [monthly]
Completed PHASE1_PHASE2
-
May 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2019 — May 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2019 — Jun 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Feb 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Stemline Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .